User:Mr. Ibrahem/Lonafarnib

Mr. Ibrahem/Lonafarnib
Clinical data
Trade names	Zokinvy
Other names	SCH 66336
AHFS/Drugs.com	Monograph
License data	US DailyMed: Lonafarnib;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 4-(2-{4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperidin-1-yl}-2-oxoethyl)piperidine-1-carboxamide;
Chemical and physical data
Formula	C27H31Br2ClN4O2
Molar mass	638.83 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=12CCC=3C=C(C=C(C3[C@H](C1N=CC(=C2)Br)C4CCN(CC4)C(=O)CC5CCN(CC5)C(N)=O)Br)Cl;
	InChI InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1 ; Key:DHMTURDWPRKSOA-RUZDIDTESA-N ;

Lonafarnib, sold under the brand name Zokinvy, is a medication used to treat Hutchinson-Gilford progeria syndrome and certain processing-deficient progeroid laminopathies.^[1] It is used in people starting at a year old.^[1] It is taken by mouth.^[1]

Common side effects included nausea, headache, diarrhea, infection, muscle pain, electrolyte problems, weight loss, bone marrow suppression, liver inflammation, high blood pressure, and tiredness.^[1] Other side effects may include kidney problems, vision problems, and decreased fertility.^[1] Use during pregnancy may harm the baby.^[1] It is a farnesyltransferase inhibitor.^[1]

Lonafarnib was approved for medical use in the United States in 2020 and Europe in 2022.^[1]^[2] In the United States, at the initial dose of 50 mg twice per day, it costs about 50,000 USD per month as of 2022.^[3]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Lonafarnib capsule". DailyMed. Archived from the original on 22 January 2021. Retrieved 17 January 2021.
^ ^a ^b "Zokinvy EPAR". European Medicines Agency. 17 May 2022. Archived from the original on 2 August 2022. Retrieved 1 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Zokinvy Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 21 May 2022. Retrieved 3 November 2022.

[PI2022-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Lonafarnib capsule". DailyMed. Archived from the original on 22 January 2021. Retrieved 17 January 2021.

[EPAR2022-2] "Zokinvy EPAR". European Medicines Agency. 17 May 2022. Archived from the original on 2 August 2022. Retrieved 1 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[3] "Zokinvy Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 21 May 2022. Retrieved 3 November 2022.

[1]

[2]

[3]